```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSPTAMXG1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 28   PATDPAFULL - New display fields provide for legal status
                   data from INPADOC
 NEWS  4  FEB 28   BABS - Current-awareness alerts (SDIs) available
 NEWS  5  MAR 02   GBFULL: New full-text patent database on STN
 NEWS  6  MAR 03   REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  7  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 22   KOREAPAT now updated monthly; patent information enhanced
 NEWS  9  MAR 22   Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  10 MAR 22   PATDPASPC - New patent database available
 NEWS  11 MAR 22   REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  12 APR 04   EPFULL enhanced with additional patent information and new
                   fields
 NEWS  13 APR 04   EMBASE - Database reloaded and enhanced
 NEWS  14 APR 18   New CAS Information Use Policies available online
 NEWS  15 APR 25   Patent searching, including current-awareness alerts (SDIs),
                   based on application date in CA/CAplus and USPATFULL/USPAT2
                   may be affected by a change in filing date for U.S.
                   applications.
 NEWS  16 APR 28   Improved searching of U.S. Patent Classifications for
                   U.S. patent records in CA/CAplus
 NEWS  17 MAY 23   GBFULL enhanced with patent drawing images
 NEWS  18 MAY 23   REGISTRY has been enhanced with source information from
                   CHEMCATS
 NEWS  19 JUN 06   The Analysis Edition of STN Express with Discover!
                   (Version 8.0 for Windows) now available
 NEWS  20 JUN 13   RUSSIAPAT: New full-text patent database on STN
 NEWS  21 JUN 13   FRFULL enhanced with patent drawing images
 NEWS  22 JUN 27   MARPAT displays enhanced with expanded G-group definitions
                   and text labels
 NEWS  23 JUL 01   MEDICONF removed from STN
 NEWS  24 JUL 07   STN Patent Forums to be held in July 2005
 NEWS  25 JUL 13   SCISEARCH reloaded
 NEWS  26 JUL 20   Powerful new interactive analysis and visualization software,
                   STN AnaVist, now available
 NEWS  27 AUG 11   Derwent World Patents Index(R) web-based training during
                   August
 NEWS  28 AUG 11   STN AnaVist workshops to be held in North America
 NEWS  29 AUG 30   CA/CAplus -Increased access to 19th century research documents
 NEWS  30 AUG 30   CASREACT - Enhanced with displayable reaction conditions

 NEWS EXPRESS  JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
```

```
 NEWS PHONE     Direct Dial and Telecommunication Network Access to STN
 NEWS WWW       CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:15:29 ON 07 SEP 2005

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:15:39 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 SEP 2005  HIGHEST RN 862534-94-9
DICTIONARY FILE UPDATES:   6 SEP 2005  HIGHEST RN 862534-94-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Documents and Settings\mgraffeo\My Documents\Critical
Data\10533077\compound.str
```



chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
chain bonds :
8-10 10-11 10-12 12-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18
exact/norm bonds :
5-7 6-9 7-8 8-9 8-10 10-11 10-12
exact bonds :
12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L1 STRUCTURE UPLOADED

=> s l1 sss full
FULL SEARCH INITIATED 11:15:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2552 TO ITERATE

100.0% PROCESSED 2552 ITERATIONS 2382 ANSWERS
SEARCH TIME: 00.00.01

L2 2382 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 11:16:03 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

```
FILE COVERS 1907 - 7 Sep 2005  VOL 143 ISS 11
FILE LAST UPDATED: 6 Sep 2005  (20050906/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l2
L3         4437 L2

=> s l3 and  (fenoctime or "oleic acid" or catechin or scopadulciol or pentagalloyl
or bufalin or bafilomycin or concanamycin) and ige and allerg and (asthma or
urticaria or anaphylaxis or rhinitis or bronchiectasis or dermatitis or malaria)
AND IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l3 and (fenoctime or "oleic acid" or catechin or scopadulciol or pentagalloyl
or bufalin or bafilomycin or concanamycin) and ige and allerg and (asthma or
urticaria or anaphylaxis or rhinitis or bronchiectasis or dermatitis or malaria)
             0 FENOCTIME
         61237 "OLEIC"
       4030191 "ACID"
         52124 "OLEIC ACID"
                 ("OLEIC"(W)"ACID")
          7807 CATECHIN
            19 SCOPADULCIOL
            74 PENTAGALLOYL
           333 BUFALIN
          1157 BAFILOMYCIN
           301 CONCANAMYCIN
         19865 IGE
             5 ALLERG
         28236 ASTHMA
          2027 URTICARIA
         10736 ANAPHYLAXIS
          5122 RHINITIS
           523 BRONCHIECTASIS
         15489 DERMATITIS
         15736 MALARIA
L4           0 L3 AND (FENOCTIME OR "OLEIC ACID" OR CATECHIN OR SCOPADULCIOL
               OR PENTAGALLOYL OR BUFALIN OR BAFILOMYCIN OR CONCANAMYCIN) AND
               IGE AND ALLERG AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS OR RHINIT
               IS OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)

=> s l3 and and ige and allerg and (asthma or urticaria or anaphylaxis or rhinitis
or bronchiectasis or dermatitis or malaria)
MISSING TERM 'AND AND'
The search profile that was entered contains a logical
operator followed immediately by another operator.

=> s l3 and ige and allerg and (asthma or urticaria or anaphylaxis or rhinitis or
bronchiectasis or dermatitis or malaria)
         19865 IGE
             5 ALLERG
         28236 ASTHMA
          2027 URTICARIA
         10736 ANAPHYLAXIS
          5122 RHINITIS
           523 BRONCHIECTASIS
         15489 DERMATITIS
         15736 MALARIA
L5           0 L3 AND IGE AND ALLERG AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS
```

```
                OR RHINITIS OR BRONCHIECTASIS OR DEPMATITIS OR MALARIA)

=> s l3 and ige and allerg? and (asthma or urticaria or anaphylaxis or rhinitis or
bronchiectasis or dermatitis or malaria)
         19865 IGE
         62330 ALLERG?
         28236 ASTHMA
          2027 URTICARIA
         10736 ANAPHYLAXIS
          5122 RHINITIS
           523 BRONCHIECTASIS
         15489 DERMATITIS
         15736 MALARIA
L6           4 L3 AND IGE AND ALLERG? AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS
               OR RHINITIS OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)

=> s l3 and (fenoctime or "oleic acid" or catechin or scopadulciol or pentagalloyl
or bufalin or bafilomycin or concanamycin) and ige and allerg? and (asthma or
urticaria or anaphylaxis or rhinitis or bronchiectasis or dermatitis or malaria)
             0 FENOCTIME
         61237 "OLEIC"
       4030191 "ACID"
         52124 "OLEIC ACID"
                 ("OLEIC"(W)"ACID")
          7807 CATECHIN
            19 SCOPADULCIOL
            74 PENTAGALLOYL
           333 BUFALIN
          1157 BAFILOMYCIN
           301 CONCANAMYCIN
         19865 IGE
         62330 ALLERG?
         28236 ASTHMA
          2027 URTICARIA
         10736 ANAPHYLAXIS
          5122 RHINITIS
           523 BRONCHIECTASIS
         15489 DERMATITIS
         15736 MALARIA
L7           1 L3 AND (FENOCTIME OR "OLEIC ACID" OR CATECHIN OR SCOPADULCIOL
               OR PENTAGALLOYL OR BUFALIN OR BAFILOMYCIN OR CONCANAMYCIN) AND
               IGE AND ALLERG? AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS OR RHINI
               TIS OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)

=> d bib abs

L7   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:412815  CAPLUS
DN   140:386032
TI   Composition using a benzimidazolic compound with proton pump inhibitor
     activity for preventing secretion of immunoglobulin E-dependent histamine
     releasing factor
IN   Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
PA   S. Korea
SO   PCT Int. Appl., 29 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2004041280        A1    20040521    WO 2003-KR2332         20031103
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS,
```

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI KR 2002-67653 A 20021102
KR 2003-75511 A 20031028

AB The invention discloses a composition for inhibiting the secretion of an **IgE**-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, **oleic acid**, **catechin**, **scopadulciol**, **pentagalloyl** glucose, **bufalin**, and macrolide antibiotic **bafilomycin** and **concanamycin**, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient. The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various **allergic** diseases and **malaria**, which are caused by the **IgE**-dependent histamine-releasing factor.

=> s l6
19865 IGE
62330 ALLERG?
28236 ASTHMA
2027 URTICARIA
10736 ANAPHYLAXIS
5122 RHINITIS
523 BRONCHIECTASIS
15489 DERMATITIS
15736 MALARIA
L8 4 L3 AND IGE AND ALLERG? AND (ASTHMA OR URTICARIA OR ANAPHYLAXIS OR RHINITIS OR BRONCHIECTASIS OR DERMATITIS OR MALARIA)

=> d 1-4 bib abs hitstr

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:834661 CAPLUS
DN 142:348646
TI Recurrent **anaphylaxis** linked to pantoprazole
AU Kollmeier, Alexa P.; Eddleston, Jane; Zuraw, Bruce L.; Christiansen, Sandra C.
CS Department of Asthma, Allergy and Immunol., Scripps Clin., La Jolla, CA, 92037, USA
SO Journal of Allergy and Clinical Immunology (2004), 114(4), 975-977
CODEN: JACIBY; ISSN: 0091-6749
PB Elsevier Inc.
DT Journal
LA English
AB The case of a 47-yr-old man with recurrent **anaphylaxis** induced by pantoprazole, a benzimidazole proton pump inhibitor, is presented. In this patient, the pos. skin test response and increased tryptase level are consistent with prior case reports of proton pump inhibitor anaphylaxis and suggest an immediate hypersensitivity mechanism. Although mutations in the CYP2C19 gene were not identified, the timing of anaphylactic events invokes the possible involvement of modifying pharmacogenetic factors, variations in relative levels of drug-specific **IgE**, or both.
IT **102625-70-7**, Pantoprazole **138786-67-1**, Protonix
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(recurrent **anaphylaxis** linked to pantoprazole)

RN 102625-70-7 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 138786-67-1 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:412815 CAPLUS
DN 140:386032
TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor
IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
PA S. Korea
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004041280	A1	20040521	WO 2003-KR2332	20031103

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI KR 2002-67653 A 20021102
KR 2003-75511 A 20031028

AB The invention discloses a composition for inhibiting the secretion of an IgE-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound

having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient. The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various **allergic** diseases and **malaria**, which are caused by the **IgE** -dependent histamine-releasing factor.

IT **73590-58-6**, Omeprazole **102625-70-7**, Pantoprazole **103577-45-3**, Lansoprazole **117976-89-3**, Rabeprazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzimidazolic compound with proton pump inhibitor activity for preventing secretion of **IgE**-dependent histamine releasing factor)

RN 73590-58-6 CAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 102625-70-7 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 117976-89-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:223222 CAPLUS
DN 137:257592
TI T-cell reactions to drugs in distinct clinical manifestations of drug **allergy**
AU Neukomm, Corinne B.; Yawalkar, Nikhil; Helbling, Arthur; Pichler, Werner J.
CS Division of Allergology, Clinic of Rheumatology and Clinical Immunology/Allergology, Inselspital, Bern, Switz.
SO Journal of Investigational Allergology and Clinical Immunology (2001), 11(4), 275-284
CODEN: JIAIEF; ISSN: 1018-9068
PB Hogrefe & Huber Publishers
DT Journal
LA English
AB Recent data indicate that T cells play a major role in different forms of drug **allergies.** To show that T-cell reactions are involved in various forms of adverse reactions to different kinds of drugs, and that lymphocyte transformation and skin tests may be pos. in patients who had distinct clin. manifestations of drug **allergies.** We collected data of 44 patients with a highly suggestive history for adverse drug reaction who had on subsequent investigations a pos. lymphocyte transformation test. In 41/44 patients (93%) skin tests with the suspected drugs were performed and in some cases drug-specific **IgE** -antibodies were determined All patients were HLA typed. Clin. manifestations of the drug **allergy** were heterogeneous, comprising maculopapular and bullous exanthema, erythema exsudativum multiforme, vasculitis, serum sickness, **urticaria**, as well as involvement of internal organs. Maculopapular exanthemas formed the largest group (54%), followed by reactions more indicative of immediate hypersensitivity (28%), such as **urticaria**/angioedema. In most cases (63%), β-lactam antibiotics were found to have caused the **allergic** reaction. Skin tests for immediate reactions were pos. in 6/40 patients (15%) tested, those for late reactions in 24/38 patients (63%) tested. Our data provide evidence that drug-specific T cells can be detected in distinct clin. manifestations of drug **allergy.** A combined approach using a detailed case history, lymphocyte transformation tests, skin tests (immediate and delayed type) appears to be helpful to identifying the incriminated drug.
IT **103577-45-3**, Agopton
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T-cell reactions to drugs in distinct clin. manifestations of drug **allergy**)
RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:125206 CAPLUS
DN 137:210620
TI TU-572, a Potent and Selective CD45 Inhibitor, Suppresses **IgE**-Mediated **Anaphylaxis** and Murine Contact Hypersensitivity Reactions
AU Hamaguchi, Takuya; Takahashi, Akiko; Manaka, Akira; Sato, Masakazu; Osada, Hiroyuki
CS Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama-shi, Japan
SO International Archives of Allergy and Immunology (2001), 126(4), 318-324
CODEN: IAAIEG; ISSN: 1018-2438
PB S. Karger AG
DT Journal
LA English
AB Background: CD45, receptor-type protein tyrosine phosphatases (PTPases) are essential components of signaling through both the T cell receptor and the B cell antigen receptor. However, the functional significance of CD45 in the signaling pathway through the high-affinity Ig (Ig) E receptor has not yet been established. In this study, we demonstrate that the potent CD45 inhibitor neg. regulates **IgE**-dependent **anaphylaxis** and contact hypersensitivity reactions. Method: We have previously found that TU-572, 2-[(4-methylthiopyridin-2-yl)methylsulfinyl]-5-isopropoxybenzimidazole, had a potent and selective inhibitory effect against PTPase activity of CD45. Using a CD45 inhibitor, we examined in vitro and in vivo **IgE**-mediated responses. Results: TU-572 potently inhibited histamine release from rat peritoneal mast cells and mouse systemic **anaphylaxis** reaction using monoclonal anti-dinitrophenyl (DNP) **IgE** and DNP-BSA. TU-572 also suppressed the immediate-type hypersensitivity response induced by repeated epicutaneous application of trinitrochlorobenzene in BALB/c mice. Conclusion: These findings revealed that the PTPase activity of CD45 played a critical role in signal transduction of **IgE**-mediated **anaphylaxis** in vitro and in vivo. PTPase inhibitors such as TU-572 are useful in the treatment of **allergic** diseases.
IT **326592-39-6**, TU 572
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TU-572, a potent and selective CD45 inhibitor, suppresses **IgE**-mediated **anaphylaxis** and murine contact hypersensitivity reactions)
RN 326592-39-6 CAPLUS
CN 1H-Benzimidazole, 5-(1-methylethoxy)-2-[[[4-(methylthio)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



```
RE.CNT  37    THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> FIL STNGUIDE
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                  145.98     307.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -3.65      -3.65

FILE 'STNGUIDE' ENTERED AT 11:22:08 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep  2, 2005 (20050902/UP).

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.06     307.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -3.65

FILE 'CAPLUS' ENTERED AT 11:22:59 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Sep 2005  VOL 143 ISS 11
FILE LAST UPDATED: 6 Sep 2005  (20050906/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l3
L9         4437 L2

=> s wo2004041280/pn
L10           1 WO2004041280/PN
                (WO2004041280/PN)

=> sel rn
E1 THROUGH E17 ASSIGNED
```

```
=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         3.32     310.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -3.65

FILE 'REGISTRY' ENTERED AT 11:24:49 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 SEP 2005  HIGHEST RN 862534-94-9
DICTIONARY FILE UPDATES:   6 SEP 2005  HIGHEST RN 862534-94-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s e1-e17
             1 102625-70-7/BI
               (102625-70-7/RN)
             1 103577-45-3/BI
               (103577-45-3/RN)
             1 112-80-1/BI
               (112-80-1/RN)
             1 117976-89-3/BI
               (117976-89-3/RN)
             1 136565-26-9/BI
               (136565-26-9/RN)
             1 151499-39-7/BI
               (151499-39-7/RN)
             1 154-23-4/BI
               (154-23-4/RN)
             1 4091-50-3/BI
               (4091-50-3/RN)
             1 465-21-4/BI
               (465-21-4/RN)
             1 50-00-0/BI
               (50-00-0/RN)
```

```
              1 50-78-2/BI
                (50-78-2/RN)
              1 50678-27-8/BI
                (50678-27-8/RN)
              1 51-17-2/BI
                (51-17-2/RN)
              1 51-45-6/BI
                (51-45-6/RN)
              1 69365-65-7/BI
                (69365-65-7/RN)
              1 73590-58-6/BI
                (73590-58-6/RN)
              1 80890-47-7/BI
                (80890-47-7/RN)
L11          17 (102625-70-7/BI OR 103577-45-3/BI OR 112-80-1/BI OR 117976-89-3/
                BI OR 136565-26-9/BI OR 151499-39-7/BI OR 154-23-4/BI OR 4091-50
                -3/BI OR 465-21-4/BI OR 50-00-0/BI OR 50-78-2/BI OR 50678-27-8/B
                I OR 51-17-2/BI OR 51-45-6/BI OR 69365-65-7/BI OR 73590-58-6/BI
                OR 80890-47-7/BI)

=> d1-17
D1-17 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d 1-17

L11  ANSWER 1 OF 17  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   151499-39-7  REGISTRY
ED   Entered STN:  01 Dec 1993
CN   Bafilomycin (9CI)  (CA INDEX NAME)
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2,
       USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
               63 REFERENCES IN FILE CA (1907 TO DATE)
                2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
               63 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11  ANSWER 2 OF 17  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   136565-26-9  REGISTRY
ED   Entered STN:  04 Oct 1991
CN   9,11a-Methano-11aH-cyclohepta[a]naphthalen-8(9H)-one, 5-
     (benzoyloxy)dodecahydro-4-(hydroxymethyl)-4,9,11b-trimethyl-,
     (4R,4aR,5R,6aS,9S,11aS,11bS)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   9,11a-Methano-11aH-cyclohepta[a]naphthalen-8(9H)-one, 5-
     (benzoyloxy)dodecahydro-4-(hydroxymethyl)-4,9,11b-trimethyl-,
     [4R-(4α,4aα,5β,6aβ,9β,11aβ,11bβ)]-
OTHER NAMES:
CN   Scopadulciol
MF   C27 H36 O4
SR   CA
LC   STN Files:   ADISINSIGHT, AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAPLUS, IPA,
       MEDLINE, TOXCENTER
         (*File contains numerically searchable property data)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 3 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **117976-89-3** REGISTRY
ED Entered STN: 16 Dec 1988
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[[[3-Methyl-4-(3-methoxypropoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CN 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CN 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]benzimidazole
CN LY 307640
CN Pariets
CN Rabeprazole
FS 3D CONCORD
MF C18 H21 N3 O3 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

464 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
466 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 4 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **103577-45-3** REGISTRY
ED Entered STN: 02 Aug 1986
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-

pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (±)-Lansoprazole

CN 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole

CN A 65006

CN AG 1749

CN Agopton

CN Ilsatec

CN Ketian

CN Lancid

CN Lanfast

CN Lanproton

CN Lansopep

CN Lansophed

CN Lansoprazole

CN Lansox

CN Lanston

CN Lanz

CN Lanzol 30

CN Lanzopral

CN Lanzor

CN Lapraz

CN Ogast

CN Ogastro

CN PP/K-10

CN Prevacid

CN Promp

CN Prosogan

CN Suprecid

CN Takepron

CN Ulpax

CN Zoton

FS 3D CONCORD

DR 154727-72-7

MF C16 H14 F3 N3 O2 S

CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1246 REFERENCES IN FILE CA (1907 TO DATE)

17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1251 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 5 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN

RN 102625-70-7 REGISTRY

ED Entered STN: 14 Jun 1986
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl] (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
CN 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
CN BY 1023
CN Pantoprazole
CN Pantozol
CN SKF 96022
FS 3D CONCORD
DR 154644-14-1
MF C16 H15 F2 N3 O4 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PROMT, PROUSDDR, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

645 REFERENCES IN FILE CA (1907 TO DATE)
20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
649 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 6 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **80890-47-7** REGISTRY
ED Entered STN: 16 Nov 1984
CN Oxacyclooctadeca-3,5,13,15-tetraen-2-one, 18-[(1S,2R,3S)-3-[(2R,4R,5S,6R)-4-[[4-O-(aminocarbonyl)-2,6-dideoxy-β-D-arabino-hexopyranosyl]oxy]tetrahydro-2-hydroxy-5-methyl-6-(1E)-1-propenyl-2H-pyran-2-yl]-2-hydroxy-1-methylbutyl]-9-ethyl-8,10-dihydroxy-3,17-dimethoxy-5,7,11,13-tetramethyl-, (3Z,5E,7R,8R,9S,10S,11R,13E,15E,17S,18R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Concanamycin A
CN Oxacyclooctadecane, concanamycin A deriv.
OTHER NAMES:
CN Antibiotic X 4357B
CN Concanamycin
CN X 4357B
CN [7R-[3Z,5E,7R*,8R*,9S*,10S*,11R*,13E,15E,17S*,18R*[1S*,2R*,3S*[2R*,4R*,5S*,6R*(E)]]]-18-[3-[4-[[4-O-(Aminocarbonyl)-2,6-dideoxy-β-D-arabino-hexopyranosyl]oxy]tetrahydro-2-hydroxy-5-methyl-6-(1-propenyl)-2H-pyran-2-yl]-2-hydroxy-1-methylbutyl]-9-ethyl-8,10-dihydroxy-3,17-dimethoxy-5,7,11,13-tetramethyloxacyclooctadeca-3,5,13,15-tetraen-2-one

FS STEREOSEARCH
DR 6?771-59-3
MF C46 H75 N O14
CI COM
LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, MEDLINE, NAPRALERT, RTECS*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

103 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
103 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 7 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN 73590-58-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (±)-Omeprazole
CN 2-[[(3,5-Dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]-5-methoxy-1H-benzimidazole

CN 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
CN Acidex
CN Antra
CN Antra MUPS
CN Audazol
CN Aulcer
CN Belmazol
CN Ceprandal
CN Desec
CN Dizprazol
CN Dudencer
CN Elgam
CN Emeproton
CN Epirazole
CN Gastrimut
CN GastroGard
CN Gastroloc
CN Gastrozole
CN Gibancer
CN H 168/68
CN Indurgan
CN Inhibitron
CN Inhipump
CN Logastric
CN Lomac
CN Losec
CN Mepral
CN Miol
CN Miracid
CN Mopral
CN Ocid
CN Omapren
CN Omebeta 20
CN Omed
CN Omedar
CN OMEP
CN Omepradex
CN Omepral
CN Omeprazen
CN Omeprazole
CN Omeprazon
CN Omepril
CN Omezol
CN Omezzol
CN Omid
CN Omisec
CN Omizac
CN OMP
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS 3D CONCORD
DR 172964-80-6, 131959-78-9
MF C17 H19 N3 O3 S
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3026 REFERENCES IN FILE CA (1907 TO DATE)
56 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3036 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 8 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **69365-65-7** REGISTRY
ED Entered STN: 16 Nov 1984
CN Piperidine, 4-(diphenylmethyl)-1-[(octylimino)methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Fenoctimin
CN Fenoctimine
FS 3D CONCORD
MF C27 H38 N2
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, DDFU, DRUGU, EMBASE, SYNTHLINE, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1907 TO DATE)
10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 9 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **50678-27-8** REGISTRY
ED Entered STN: 16 Nov 1984
CN D-Glucopyranose, pentakis(3,4,5-trihydroxybenzoate) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN D-Glucose, pentagallate (7CI)
OTHER NAMES:
CN 1,2,3,4,6-Pentagalloyl-D-glucose
CN CJ 90002
CN D-Glucose, 1,2,3,4,6-pentagallate
CN Penta-O-galloyl-D-glucose
CN Pentagalloylglucose
FS STEREOSEARCH
DR 126420-90-4, 147370-08-9, 40410-94-4
MF C41 H32 O26
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, DDFU, DRUGU, EMBASE, IPA, MEDLINE, NAPRALERT, PHAR,

TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

99 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
99 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 10 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **4091-50-3** REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzeneethanamine, 4-methoxy-N-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenethylamine, p-methoxy-N-methyl- (6CI, 8CI)
OTHER NAMES:
CN (p-Methoxyphenethyl)methylamine
CN 4-Methoxy-N-methylbenzeneethanamine
CN 4-Methoxy-N-methylphenethylamine
CN N-(p-Methoxyphenethyl)methylamine
CN N-Methyl-(p-methoxyphenethyl)amine
CN N-Methyl-β-(4-methoxyphenyl)ethylamine
CN N-Methyl-2-(4-methoxyphenyl)ethylamine
CN N-Methyl-4-methoxy-β-phenethylamine
CN N-Methyl-4-methoxyphenethylamine
CN N-Methyl-N-(4-methoxyphenethyl)amine
CN p-Methoxy-N-methylphenethylamine
CN [2-(4-Methoxyphenyl)ethyl]methylamine
FS 3D CONCORD

MF C10 H15 N O
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, NAPRALERT, NIOSHTIC, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1151 REFERENCES IN FILE CA (1907 TO DATE)
745 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1151 REFERENCES IN FILE CAPLUS (1907 TO DATE)
15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 11 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **465-21-4** REGISTRY
ED Entered STN: 16 Nov 1984
CN Bufa-20,22-dienolide, 3,14-dihydroxy-, (3β,5β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5β-Bufa-20,22-dienolide, 3β,14-dihydroxy- (7CI, 8CI)
CN Bufalin (6CI)
OTHER NAMES:
CN NSC 89595
FS STEREOSEARCH
DR 2381-02-4
MF C24 H34 O4
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, PROMT, RTECS*, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

295 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
296 REFERENCES IN FILE CAPLUS (1907 TO DATE)
36 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 12 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **154-23-4** REGISTRY
ED Entered STN: 16 Nov 1984
CN 2H-1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-, (2R,3S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2H-1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-, (2R-trans)-
CN Catechol (8CI)
OTHER NAMES:
CN (+)-(2R:3S)-5,7,3',4'-Tetrahydroxyflavan-3-ol
CN (+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol
CN (+)-Catechin
CN (+)-Catechol
CN (+)-Cianidanol
CN (+)-Cyanidan-3-ol
CN (+)-Cyanidanol
CN (+)-Cyanidanol-3
CN (2R,3S)-(+)-Catechin
CN 3-Cyanidanol, (+)-
CN Biocatechin
CN Catechin
CN Catechin (flavan)
CN Catechinic acid
CN Catechol (flavan)
CN Catechuic acid
CN Catergen
CN Cianidanol
CN Cyanidanol
CN Cyanidol
CN D-(+)-Catechin
CN D-Catechin
CN d-Catechin
CN D-Catechol
CN Dexcyanidanol
CN NSC 2919
CN Sunkatol No. 1

CN Teafuran 30A
CN trans-(+)-3,3',4',5,7-Flavanpentol
FS STEREOSEARCH
DR 523994-21-0, 321-01-7, 16198-00-8, 4211-28-3, 5323-80-8, 159761-73-6, 379227-23-3
MF C15 H14 O6
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PDLCOM*, PHAR, PIRA, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6273 REFERENCES IN FILE CA (1907 TO DATE)
328 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6284 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 13 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **112-80-1** REGISTRY
ED Entered STN: 16 Nov 1984
CN 9-Octadecenoic acid (9Z)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9-Octadecenoic acid (Z)-
CN Oleic acid (8CI)
OTHER NAMES:
CN Δ9-cis-Octadecenoic acid
CN Δ9-cis-Oleic acid
CN 9-cis-Octadecenoic acid
CN 9-Octadecenoic acid, (Z)-
CN 9Z-Octadecenoic acid
CN cis-Δ9-Octadecenoic acid
CN cis-9-Octadecenoic acid
CN cis Oleic acid
CN D 100
CN D 100 (fatty acid)
CN Edenor ATiO5
CN Edenor FTiO5
CN Emersol 205
CN Emersol 211
CN Emersol 213NF
CN Emersol 214NF

CN Emersol 233
CN Emersol 6313NF
CN Extra Oleic 80R
CN Extra Oleic 90
CN Extra Oleic 99
CN Extra Olein 80
CN Extra Olein 90R
CN Extraolein 90
CN Industrene 105
CN Lunac O-CA
CN Lunac O-LL
CN Lunac O-P
CN Lunac OA
CN NAA 35
CN Neo-Fat 92-04
CN Oleine 7503
CN Pamolyn 100
CN Priolene 6906
CN Priolene 6907
CN Priolene 6928
CN Priolene 6930
CN Priolene 6933
CN Vopcolene 27
CN Wecoline OO
CN Z-9-Octadecenoic acid
FS STEREOSEARCH
DR 8046-01-3, 56833-51-3, 17156-84-2
MF C18 H34 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PATDPASPC, PDLCOM*, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

45296 REFERENCES IN FILE CA (1907 TO DATE)
2559 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
45372 REFERENCES IN FILE CAPLUS (1907 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 14 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN 51-45-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Imidazole-4-ethanamine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Histamine (8CI)
OTHER NAMES:
CN β-Imidazolyl 4-ethylamine
CN 2-(1H-Imidazol-4-yl)ethanamine

CN 2-(1H-Imidazol-4-yl)ethylamine
CN 2-(1H-Imidazol-5-yl)ethanamine
CN 2-(1H-Imidazol-5-yl)ethylamine
CN 2-(4-Imidazolyl)ethanamine
CN 2-(4-Imidazolyl)ethylamine
CN 4-(2-Aminoethyl)imidazole
CN 5-Imidazoleethylamine
CN Eramin
CN Ergamine
CN Ergotidine
CN Imidazole-4-ethylamine
CN NSC 33792
FS 3D CONCORD
MF C5 H9 N3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

34678 REFERENCES IN FILE CA (1907 TO DATE)
479 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
34687 REFERENCES IN FILE CAPLUS (1907 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 15 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **51-17-2** REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Benzimidazole (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzimidazole (6CI, 8CI)
OTHER NAMES:
CN 1,3-Benzodiazole
CN 1,3-Diazaindene
CN 3-Azaindole
CN Azindole
CN Benziminazole
CN Benzoglyoxaline
CN Benzoimidazole
CN BZI
CN N,N'-Methenyl-o-phenylenediamine
CN NSC 759
CN o-Benzimidazole
FS 3D CONCORD
DR 25463-25-6, 79351-71-6, 116421-27-3
MF C7 H6 N2
CI COM, RPS
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,

CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6040 REFERENCES IN FILE CA (1907 TO DATE)
1881 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6047 REFERENCES IN FILE CAPLUS (1907 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 16 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **50-78-2** REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-(Acetyloxy)benzoic acid
CN 2-Acetoxybenzoic acid
CN 2-Carboxyphenyl acetate
CN A.S.A. Empirin
CN AC 5230
CN Acenterine
CN Acesal
CN Acesan
CN Acetard
CN Aceticyl
CN Acetilum acidulatum
CN Acetisal
CN Acetol
CN Acetonyl
CN Acetophen
CN Acetosal
CN Acetosalic acid
CN Acetosalin
CN Acetylin
CN Acetylsal
CN Acetylsalicylic acid
CN Acetyonyl
CN Acetysal
CN Acidum acetylsalicylicum
CN Acimetten
CN Acisal
CN Acylpyrin
CN Adiro
CN Albyl E
CN ASA
CN Asaflow
CN Asagran
CN Asatard
CN Ascoden 30
CN Ascolong
CN Ascriptin

CN Aspalon
CN Aspergum
CN Aspirdrops
CN Aspirin
CN Aspirin Protect 100
CN Aspirin Protect 300
CN Aspirin-Direkt
CN Aspirina 03
CN Aspro
CN Aspro Clear
CN Aspropharm
CN Asteric
CN Bayer
CN Benaspir
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS 3D CONCORD
DR 11126-35-5, 11126-37-7, 98201-60-6, 2349-94-2, 26914-13-6
MF C9 H8 O4
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PATDPASPC, PDLCOM*, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

19146 REFERENCES IN FILE CA (1907 TO DATE)
372 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
19191 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L11 ANSWER 17 OF 17 REGISTRY COPYRIGHT 2005 ACS on STN
RN **50-00-0** REGISTRY
ED Entered STN: 16 Nov 1984
CN Formaldehyde (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN BFV
CN F-gen
CN Fannoform
CN Floguard 1015
CN FM 282
CN Fordor
CN Formalin
CN Formalith
CN Formic aldehyde
CN Formol
CN Fyde
CN Lysoform
CN Methaldehyde

CN Methanal
CN Methyl aldehyde
CN Methylene oxide
CN Morbicid
CN NSC 298885
CN Oxomethane
CN Oxymethylene
CN Paraform
CN Superlysoform
FS 3D CONCORD
DR 8005-38-7, 8006-07-3, 8013-13-6, 112068-71-0
MF C H2 O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, PS, RTECS*, SCISEARCH, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

68262 REFERENCES IN FILE CA (1907 TO DATE)
6511 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
68334 REFERENCES IN FILE CAPLUS (1907 TO DATE)
19 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	33.43	344.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.65

FILE 'CAPLUS' ENTERED AT 11:27:41 ON 07 SEP 2005

FILE COVERS 1907 - 7 Sep 2005 VOL 143 ISS 11
FILE LAST UPDATED: 6 Sep 2005 (20050906/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 117976-89-3/rn
           466 117976-89-3
            12 117976-89-3D
L12         457 117976-89-3/RN
                (117976-89-3 (NOTL) 117976-89-3D )

=> s 117976-89-3/rn or 103577-45-3/rn or 154644-14-1/rn or 172964-80-6/rn or
131959-78-9/rn
           466 117976-89-3
            12 117976-89-3D
           457 117976-89-3/RN
                (117976-89-3 (NOTL) 117976-89-3D )
          1251 103577-45-3
            17 103577-45-3D
          1241 103577-45-3/RN
                (103577-45-3 (NOTL) 103577-45-3D )
             0 154644-14-1
             0 154644-14-1D
             0 154644-14-1/RN
                (154644-14-1 (NOTL) 154644-14-1D )
             0 172964-80-6
             0 172964-80-6D
             0 172964-80-6/RN
                (172964-80-6 (NOTL) 172964-80-6D )
             0 131959-78-9
             0 131959-78-9D
             0 131959-78-9/RN
                (131959-78-9 (NOTL) 131959-78-9D )
L13         1434 117976-89-3/RN OR 103577-45-3/RN OR 154644-14-1/RN OR 172964-80-
                6/RN OR 131959-78-9/RN

=> s l13 and l7
L14            1 L13 AND L7

=> d bib abs hitstr

L14  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:412815  CAPLUS
DN   140:386032
TI   Composition using a benzimidazolic compound with proton pump inhibitor
     activity for preventing secretion of immunoglobulin E-dependent histamine
     releasing factor
IN   Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
PA   S. Korea
SO   PCT Int. Appl., 29 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    ------- ------------    --------
PI   WO 2004041280         A1    20040521    WO 2003-KR2332          20031103
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
             TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
```

BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI KR 2002-67653 A 20021102
KR 2003-75511 A 20031028

AB The invention discloses a composition for inhibiting the secretion of an **IgE**-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, **oleic acid**, **catechin**, **scopadulciol**, **pentagalloyl** glucose, **bufalin**, and macrolide antibiotic **bafilomycin** and **concanamycin**, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient. The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various **allergic** diseases and **malaria**, which are caused by the **IgE**-dependent histamine-releasing factor.

IT **73590-58-6**, Omeprazole **102625-70-7**, Pantoprazole **103577-45-3**, Lansoprazole **117976-89-3**, Rabeprazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzimidazolic compound with proton pump inhibitor activity for preventing secretion of **IgE**-dependent histamine releasing factor)

RN 73590-58-6 CAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 102625-70-7 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 117976-89-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



=> s l13 adn l8
MISSING OPERATOR L13 ADN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l13 and l8
L15 2 L13 AND L8

=> d 1-2 bib abs hitstr

L15 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:412815 CAPLUS
DN 140:386032
TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor
IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
PA S. Korea
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004041280	A1	20040521	WO 2003-KR2332	20031103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI KR 2002-67653	A	20021102		
KR 2003-75511	A	20031028		

AB The invention discloses a composition for inhibiting the secretion of an **IgE**-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient. The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various allergic

diseases and **malaria**, which are caused by the **IgE**-dependent histamine-releasing factor.

IT 73590-58-6, Omeprazole 102625-70-7, Pantoprazole **103577-45-3**, Lansoprazole **117976-89-3**, Rabeprazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzimidazolic compound with proton pump inhibitor activity for preventing secretion of **IgE**-dependent histamine releasing factor)

RN 73590-58-6 CAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 102625-70-7 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 117976-89-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:223222 CAPLUS

DN 137:257592
TI T-cell reactions to drugs in distinct clinical manifestations of drug **allergy**
AU Neukomm, Corinne B.; Yawalkar, Nikhil; Helbling, Arthur; Pichler, Werner J.
CS Division of Allergology, Clinic of Rheumatology and Clinical Immunology/Allergology, Inselspital, Bern, Switz.
SO Journal of Investigational Allergology and Clinical Immunology (2001), 11(4), 275-284
CODEN: JIAIEF; ISSN: 1018-9068
PB Hogrefe & Huber Publishers
DT Journal
LA English
AB Recent data indicate that T cells play a major role in different forms of drug **allergies.** To show that T-cell reactions are involved in various forms of adverse reactions to different kinds of drugs, and that lymphocyte transformation and skin tests may be pos. in patients who had distinct clin. manifestations of drug **allergies.** We collected data of 44 patients with a highly suggestive history for adverse drug reaction who had on subsequent investigations a pos. lymphocyte transformation test. In 41/44 patients (93%) skin tests with the suspected drugs were performed and in some cases drug-specific **IgE** -antibodies were determined All patients were HLA typed. Clin. manifestations of the drug **allergy** were heterogeneous, comprising maculopapular and bullous exanthema, erythema exsudativum multiforme, vasculitis, serum sickness, **urticaria**, as well as involvement of internal organs. Maculopapular exanthemas formed the largest group (54%), followed by reactions more indicative of immediate hypersensitivity (28%), such as **urticaria**/angioedema. In most cases (63%), β-lactam antibiotics were found to have caused the **allergic** reaction. Skin tests for immediate reactions were pos. in 6/40 patients (15%) tested, those for late reactions in 24/38 patients (63%) tested. Our data provide evidence that drug-specific T cells can be detected in distinct clin. manifestations of drug **allergy.** A combined approach using a detailed case history, lymphocyte transformation tests, skin tests (immediate and delayed type) appears to be helpful to identifying the incriminated drug.
IT **103577-45-3**, Agopton
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T-cell reactions to drugs in distinct clin. manifestations of drug **allergy**)
RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (l13 or l3) and l7
L16 1 (L13 OR L3) AND L7

=> d bib

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:412815 CAPLUS
DN 140:386032
TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor
IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
PA S. Korea
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041280	A1	20040521	WO 2003-KR2332	20031103
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	KR 2002-67653	A	20021102		
	KR 2003-75511	A	20031028		

=> s (l13 or l3) and l8
L17 4 (L13 OR L3) AND L8

=> d 1-4 bib abs hitstr

L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:834661 CAPLUS
DN 142:348646
TI Recurrent **anaphylaxis** linked to pantoprazole
AU Kollmeier, Alexa P.; Eddleston, Jane; Zuraw, Bruce L.; Christiansen, Sandra C.
CS Department of Asthma, Allergy and Immunol., Scripps Clin., La Jolla, CA, 92037, USA
SO Journal of Allergy and Clinical Immunology (2004), 114(4), 975-977
CODEN: JACIBY; ISSN: 0091-6749
PB Elsevier Inc.
DT Journal
LA English
AB The case of a 47-yr-old man with recurrent **anaphylaxis** induced by pantoprazole, a benzimidazole proton pump inhibitor, is presented. In this patient, the pos. skin test response and increased tryptase level are consistent with prior case reports of proton pump inhibitor **anaphylaxis** and suggest an immediate hypersensitivity mechanism. Although mutations in the CYP2C19 gene were not identified, the timing of anaphylactic events invokes the possible involvement of modifying pharmacogenetic factors, variations in relative levels of drug-specific **IgE**, or both.
IT 102625-70-7, Pantoprazole 138786-67-1, Protonix
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(recurrent **anaphylaxis** linked to pantoprazole)
RN 102625-70-7 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 138786-67-1 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:412815 CAPLUS
DN 140:386032
TI Composition using a benzimidazolic compound with proton pump inhibitor activity for preventing secretion of immunoglobulin E-dependent histamine releasing factor
IN Lee, Kyung-Lim; Lee, Chul-Hee; Choi, Seung-Hee
PA S. Korea
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041280	A1	20040521	WO 2003-KR2332	20031103
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	KR 2002-67653	A	20021102		
	KR 2003-75511	A	20031028		

AB The invention discloses a composition for inhibiting the secretion of an IgE-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the invention contains a benzimidazolic compound having proton pump inhibitor activity as an active ingredient. Furthermore, the composition of the invention may contain at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, all having proton pump inhibitor activity, as an addnl. active ingredient or a single active ingredient.

The composition of the invention can be advantageously used as a pharmaceutical composition for the prevention and treatment of various allergic diseases and malaria, which are caused by the **IgE** -dependent histamine-releasing factor.

IT **73590-58-6**, Omeprazole **102625-70-7**, Pantoprazole **103577-45-3**, Lansoprazole **117976-89-3**, Rabeprazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzimidazolic compound with proton pump inhibitor activity for preventing secretion of **IgE**-dependent histamine releasing factor)

RN 73590-58-6 CAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 102625-70-7 CAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 117976-89-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:223222 CAPLUS
DN 137:257592
TI T-cell reactions to drugs in distinct clinical manifestations of drug **allergy**
AU Neukomm, Corinne B.; Yawalkar, Nikhil; Helbling, Arthur; Pichler, Werner J.
CS Division of Allergology, Clinic of Rheumatology and Clinical Immunology/Allergology, Inselspital, Bern, Switz.
SO Journal of Investigational Allergology and Clinical Immunology (2001), 11(4), 275-284
CODEN: JIAIEF; ISSN: 1018-9068
PB Hogrefe & Huber Publishers
DT Journal
LA English
AB Recent data indicate that T cells play a major role in different forms of drug **allergies.** To show that T-cell reactions are involved in various forms of adverse reactions to different kinds of drugs, and that lymphocyte transformation and skin tests may be pos. in patients who had distinct clin. manifestations of drug **allergies.** We collected data of 44 patients with a highly suggestive history for adverse drug reaction who had on subsequent investigations a pos. lymphocyte transformation test. In 41/44 patients (93%) skin tests with the suspected drugs were performed and in some cases drug-specific **IgE** -antibodies were determined All patients were HLA typed. Clin. manifestations of the drug **allergy** were heterogeneous, comprising maculopapular and bullous exanthema, erythema exsudativum multiforme, vasculitis, serum sickness, **urticaria**, as well as involvement of internal organs. Maculopapular exanthemas formed the largest group (54%), followed by reactions more indicative of immediate hypersensitivity (28%), such as **urticaria**/angioedema. In most cases (63%), β-lactam antibiotics were found to have caused the **allergic** reaction. Skin tests for immediate reactions were pos. in 6/40 patients (15%) tested, those for late reactions in 24/38 patients (63%) tested. Our data provide evidence that drug-specific T cells can be detected in distinct clin. manifestations of drug **allergy.** A combined approach using a detailed case history, lymphocyte transformation tests, skin tests (immediate and delayed type) appears to be helpful to identifying the incriminated drug.
IT **103577-45-3**, Agopton
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T-cell reactions to drugs in distinct clin. manifestations of drug **allergy**)
RN 103577-45-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:125206 CAPLUS
DN 137:210620
TI TU-572, a Potent and Selective CD45 Inhibitor, Suppresses IgE -Mediated **Anaphylaxis** and Murine Contact Hypersensitivity

Reactions
AU Hamaguchi, Takuya; Takahashi, Akiko; Manaka, Akira; Sato, Masakazu; Usada, Hiroyuki
CS Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama-shi, Japan
SO International Archives of Allergy and Immunology (2001), 126(4), 318-324
CODEN: IAAIEG; ISSN: 1018-2438
PB S. Karger AG
DT Journal
LA English
AB Background: CD45, receptor-type protein tyrosine phosphatases (PTPases) are essential components of signaling through both the T cell receptor and the B cell antigen receptor. However, the functional significance of CD45 in the signaling pathway through the high-affinity Ig (Ig) E receptor has not yet been established. In this study, we demonstrate that the potent CD45 inhibitor neg. regulates **IgE**-dependent **anaphylaxis** and contact hypersensitivity reactions. Method: We have previously found that TU-572, 2-[(4-methylthiopyridin-2-yl)methylsulfinyl]-5-isopropoxybenzimidazole, had a potent and selective inhibitory effect against PTPase activity of CD45. Using a CD45 inhibitor, we examined in vitro and in vivo **IgE**-mediated responses. Results: TU-572 potently inhibited histamine release from rat peritoneal mast cells and mouse systemic **anaphylaxis** reaction using monoclonal anti-dinitrophenyl (DNP) **IgE** and DNP-BSA. TU-572 also suppressed the immediate-type hypersensitivity response induced by repeated epicutaneous application of trinitrochlorobenzene in BALB/c mice. Conclusion: These findings revealed that the PTPase activity of CD45 played a critical role in signal transduction of **IgE**-mediated **anaphylaxis** in vitro and in vivo. PTPase inhibitors such as TU-572 are useful in the treatment of **allergic** diseases.
IT **326592-39-6**, TU 572
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TU-572, a potent and selective CD45 inhibitor, suppresses **IgE**-mediated **anaphylaxis** and murine contact hypersensitivity reactions)
RN 326592-39-6 CAPLUS
CN 1H-Benzimidazole, 5-(1-methylethoxy)-2-[[[4-(methylthio)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	61.96	406.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.11	-8.76

STN INTERNATIONAL LOGOFF AT 11:32:39 ON 07 SEP 2005